Early Retiree
Research analyst, value, small-cap, retirement and income

Innoviva: What Happens When Generic Advair Hits The Market?

A few days ago, Innoviva (NASDAQ:INVA) changed name (before the company had called itself Theravance (THRX)) and immediately sold off, as Mylan (NASDAQ:MYL) finally presented an ANDA for a generic Advair.

Advair is one of the most successful drugs ever, but has lost some of its luster over the past few years. Tougher competition, pricing pressure and some homemade problems at GSK (NYSE:GSK) have contributed to market share and significant revenue losses. While Advair started its decline, GSK launched a portfolio of successor products, among which Breo, partnered with Innoviva, is presumably the most important one. However, Breo's launch was slower than expected (by the market, not by management), and there is

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details